Annette Langer-Gould to Registries
This is a "connection" page, showing publications Annette Langer-Gould has written about Registries.
Connection Strength
1.154
-
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
Score: 0.191
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Score: 0.159
-
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
Score: 0.154
-
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology. 2019 03; 30(2):230-233.
Score: 0.142
-
Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016 05; 22(6):801-9.
Score: 0.115
-
Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016 05; 22(6):810-6.
Score: 0.114
-
Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol. 2015 Oct; 72(10):1132-8.
Score: 0.112
-
Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012 Dec; 259(12):2565-70.
Score: 0.089
-
Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.039
-
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
Score: 0.038